• Home
  • > R&D
  • > TaNeDS Global

Join TaNeDS Global 2018

Learn more about Daiichi Sankyo's open competition grant program

TaNeDS program provides close partnership between you and scientists in Daiichi Sankyo to tackle unmet medical needs.

The program is open to principal investigators affiliated with research institution in academia and small biotech located in Europe and the east coast of the United States.

The Deadline of Submission is February 19, 2018

What is TaNeDS?

TaNeDS (Take a New Challenge for Drug diScovery) is Daiichi Sankyo's open competition grant program. To help realize our corporate philosophy – "Passion for Innovation. Compassion for Patients." –this program serves as an interactive platform that gathers and nurtures the wisdom of researchers from diverse scientific backgrounds.

Initially launched in Japan in 2011 and in Europe in 2013, the goal of this program is to generate breakthrough pharmaceutical drugs for human health by promoting new drug discovery themes, R&D technologies, and continuous collaboration with external researchers and research groups.

In this program, we provide Our Research Interests and recruit Application Forms from principal investigators affiliated with research institution in academia and small biotech. After careful review by selected members of Daiichi Sankyo, we start the collaboration research with the winners of this program.

For the TaNeDS Europe 2017, we received 56 proposals and selected 4 projects. (Please see our Past Results.)

In 2018, this program will be expanded to the east coast of the United States where Daiichi Sankyo, Inc. is located and renamed to TaNeDS Global. We set two sizes of the grant, up to €/$ 75,000 per year (Type A) for discovery stage and up to €/$150,000 per year (Type B) for validation stage.

Research Stages

One key goal of TaNeDS Global is to foster close collaborative relationships between principal investigators of the funded projects and scientists at Daiichi Sankyo. Collaboration beyond the initial funding period is also possible for successful projects to fulfill our ultimate goal of drug development.

For more information, please see our Guidelines for Application

Our strength in R&D


Anchored by our Antibody Drug Conjugate (ADC) Franchises and Acute Myeloid Leukemia (AML) Franchises, our cancer pipeline includes more than 20 small molecules, monoclonal antibodies and ADCs stemming from our powerful research engines.


As one of new horizon areas in our R&D strategy, we are developing approaches to provide new treatment options for pain management. We have several anchor assets such as Mirogabalin at the late-stage of development.

Cardiovascular and renal diseases

Through our success on development of Olmesartan, Prasugrel, and Edoxaban, we have strong R&D expertise with deep academic relationships in cardiovascular-metabolics.

Rare Diseases

ENA® oligonucleotide is a modified nucleic acid using proprietary technology owned by Daiichi Sankyo. DS-5141, a Duchenne muscular dystrophy treatment drug containing the ENA® oligonucleotide, is currently in a Phase 1/2 clinical trial in Japan.

Who we are

Daiichi Sankyo Co., Ltd. is a proprietary pharmaceutical company with origins in Japan. Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.

For more information, please visit:

Our contribution to global health

Our R&D innovation and successes include a member of the statin class Pravastatin (Pravachol®: US, EU, licensed to Bristol-Myers Squibb) and the new quinolone class Levofloxacin (Levaquin®: US, licensed to Johnson & Johnson, Tavanic®: EU, licensed to Sanofi Aventis). Recent drugs include the angiotensin Ⅱ receptor blocker Olmesartan (Benicar®: US, Olmetec®: EU), the ADP receptor inhibitor Prasugrel (Effient®: US, Efient®: EU, co-promoted with Eli Lilly), and the FXa inhibitor Edoxaban (Savaysa®: US, Lixiana®: EU).

Our worldwide research and development network connects Japan, the United States, Europe, and East Asian countries. In Europe, the Tissue and Cell Research Center Munich performs pharmacokinetic studies and toxicity tests. In the United States, Plexxikon Inc., based in Berkley, California, is advancing R&D for oncology, from research to early-stage development.

Locations in Europe

Locations in the US

About the TaNeDS Logo

A symbol of "hope to grow by partnership." Two people facing each other, holding hands expresses the intention of collaboration, to foster the seeds of hope together.